Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects

Journal of Nephrology

Volumn 27, Issue 6, 2014, Pages 659-666

  Chong, Edward ^a   Kalia, Veena ^a   Willsie, Sandra ^b   Winkle, Peter ^c  

^a Aspreva Pharmaceuticals Corporation   (Canada)

^b PRA HEALTH SCIENCES   (United States)

^c Anaheim Clinical Trials   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Pharmacokinetics; Phase I; Sucroferric oxyhydroxide

Indexed keywords

DIGOXIN; FUROSEMIDE; LOSARTAN; OMEPRAZOLE; SUCROFERRIC OXYHYDROXIDE; WARFARIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; CARDIOTONIC AGENT; CHELATING AGENT; DIURETIC AGENT; DRUG COMBINATION; FERRIC ION; PROTON PUMP INHIBITOR; SUCROSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED CLINICAL TRIAL (TOPIC); DIALYSIS; DRUG INTERACTION; FEMALE; GASTROINTESTINAL DISEASE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RHABDOMYOLYSIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL MODEL; YOUNG ADULT;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTICOAGULANTS; AREA UNDER CURVE; CARDIOTONIC AGENTS; CHELATING AGENTS; DIGOXIN; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FERRIC COMPOUNDS; FUROSEMIDE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; LOSARTAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; OMEPRAZOLE; PROTON PUMP INHIBITORS; RISK ASSESSMENT; SUCROSE; WARFARIN; YOUNG ADULT;

EID: 84908251094     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0080-1     Document Type: Article

References (17)

1. Hruska KA, Mathew S (2011) The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chronic Kidney Dis 18:98–104
2. Block GA (2001) Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 10:741–747
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218
4. Palmer SC, Hayen A, Macaskill P et al (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119–1127
5. Kanbay M, Goldsmith D, Akcay A, Covic A (2009) Phosphate—the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 27:220–230
6. Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519–530
7. Geisser P, Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74:4–11
8. Hergesell O, Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863–867
9. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280–289
10. Floege J, Ketteler M, Rastogi A et al (2012) Efficacy and safety of PA21 in hyperphosphatemic CKD patients on dialysis. J Am Soc Nephrol 23:abstract SA-PO1103
11. Sprague S, Floege J, Covic A et al (2013) Efficacy of PA21, a novel iron-based phosphate binder, maintained to 52 weeks in dialysis patients with hyperphosphatemia. J Am Soc Nephrol 24:abstract TH-OR027
12. Rifkin DE, Winkelmayer WC (2010) Medication issues in older individuals with CKD. Adv Chronic Kidney Dis 17:320–328
13. Mason NA, Bakus JL (2010) Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial 23:55–61
14. Johnson BF, O’Grady J, Sabey GA, Bye C (1978) Effect of a standard breakfast on digoxin absorption in normal subjects. Clin Pharmacol Ther 23:315–319
15. Vaz-da-Silva M, Loureiro AI, Nunes T et al (2005) Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig 25:391–399
16. Beermann B, Midskov C (1986) Reduced bioavailability and effect of furosemide given with food. Eur J Clin Pharmacol 29:725–727
17. Sinsakul M, Sika M, Koury M et al (2012) The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 121:c25–c29